FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Approves Humacytes Symvess

[ Price : $8.95]

FDA approves Humacytes Symvess for use with some extremity arterial injuries.

FDA Alert on Boston Accolade Pacers Early Replacement

[ Price : $8.95]

FDA alerts patients, caregivers, and healthcare providers to the potential for some Boston Scientific Accolade pacemakers to need ...

Hologic BioZorb Marker Recall Class 1: FDA

[ Price : $8.95]

FDA says a Hologic 3/2024 recall correction of BioZorb Markers was Class 1.

UCB Minzasolmin Parkinsons Study Misses Endpoints

[ Price : $8.95]

UCB says it is ending the development of minzasolmin, a drug it was working on with Novartis to treat early Parkinsons disease, af...

FDA Alert on Baxter Solution Sets

[ Price : $8.95]

FDA issues an alert against the use of certain Baxter Solution Sets with Duo-Vent Spikes because they were incorrectly assembled w...

CRL for Zealands SBS Treatment NDA

[ Price : $8.95]

FDA issues a complete response letter for Zealands glepaglutide intended to treat short bowel syndrome.

Quality, Data Issues at Mylan Facility in India

[ Price : $8.95]

FDA warns a Viatris Mylan drug manufacturing facility in Pradesh, India, about CGMP violations involving quality and data issues.

Boxed Warning for Veozah Liver Injury

[ Price : $8.95]

FDA adds a liver injury Boxed Warning to labeling for Astellas menopause hot flash drug Veozah.

Sombra Cosmetics CGMP Violations

[ Price : $8.95]

FDA warns Albuquerque, NM-based Sombra Cosmetics about CGMP violations in the manufacturing of finished drugs.

FDA OKs Mesoblasts Ryoncil Cell Therapy

[ Price : $8.95]

FDA approves Mesoblasts Ryoncil to treat some graft-versus-host disease pediatric patients.